希罗达作为二线药物治疗晚期乳腺癌10例报告

A Clinical Study of Xeloda(Capecitabine) as Second Line Chemotherapy in Advanced Breast Cancer-10 Cases Report

目的 观察希罗达作为二线药物治疗晚期乳腺癌的疗效及安全性。方法 对 10例具有可测量病灶的晚期乳腺癌患者采用希罗达 ( 2 5 10mg/m2 ,每天 1次 ,连服 14天 ,2 1天为 1个周期 )单药治疗 2～ 4个周期。所有患者既往均接受过 1种以上化疗方案的化疗 ,其中 7例患者接受过阿霉素和 (或 )紫杉醇治疗。结果 10例患者中 3例接受了希罗达 2个周期化疗 ,7例完成 4个周期化疗。PR 3例 ,MR 1例 ,SD 1例 ,PD 5例。最常见的不良反应为恶心、皮肤色素沉着、厌食、疲劳和腹泻。Ⅲ度不良反应仅见于少数患者 ,其中腹泻 1例、中性粒细胞减少 1例、总胆红素升高 4例。结论 希罗达作为二线药物治疗晚期乳腺癌的疗效较好且不良反应较轻 。

Objective To observe the efficacy and safety of Xeloda as second line chemotherapy in patients with advanced breast cancer.Methods Ten patients with measurable advanced breast cancer received Xeloda at 2 510 mg/m 2/day for 2 weeks followed by a one week rest period and repeated for 2～4 cycle.All patients had received more than one course of prior chemotherapy regimens and seven patients had experienced adriamycin and paclitaxel treatment. Results Three patients received two cycles and seven patients completed four cycles treatment of Xeloda.Three partial response,one minor response,one stable disease and five progressive disease were observed among the 10 patients.The common treatment related adverse events were nausea,skin pigmentation,anorexia,fatigue and diarrhea.Grade Ⅲ side effects occurred in several patients:one neutropenia,one diarrhea and four hyper bilirubinemia.Conclusion Xeloda is an active drug in the treatment of advanced breast cancer with a favorable toxicity profile.It is possible for Xeloda to become an ideal second line treatment drug for breast cancer patients in whom anthracycline and taxane treatment has failed.